Breaking News Instant updates and real-time market news.

BIIB

Biogen

$287.44

-0.51 (-0.18%)

, PFE

Pfizer

$33.15

0.15 (0.45%)

09:01
07/31/17
07/31
09:01
07/31/17
09:01

Biogen names Anabella Villalobos as SVP, BTMS

Biogen (BIIB) announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences. Villalobos will lead Biogen's BTMS organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, M.D., Ph.D., executive vice president, Head of Research and Development. Villalobos joins Biogen from Pfizer Worldwide Research and Development (PFE) where she most recently served as Vice President and Head of Medicinal Synthesis Technologies.

BIIB

Biogen

$287.44

-0.51 (-0.18%)

PFE

Pfizer

$33.15

0.15 (0.45%)

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 27

    Aug

  • 28

    Aug

BIIB Biogen
$287.44

-0.51 (-0.18%)

07/26/17
GSCO
07/26/17
UPGRADE
Target $338
GSCO
Buy
Biogen upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn upgraded Biogen following the company's Q2 earnings report and raised his price target for the shares to $338 from $288. The drugmaker closed yesterday down $1.74 to $282.96. Biogen's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality, Flynn tells investors in a research note.
07/26/17
LEER
07/26/17
NO CHANGE
Target $338
LEER
Market Perform
Biogen price target raised to $338 from $304 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Biogen to $338 from $304 after the company reported better than expected Q2 results. While he notes that the Spinraza launch continues to beat expectations, Porges points out that management's cautious commentary about the U.S. market has left investors struggling to forecast the eventual revenue slowdown in the product's trajectory. The analyst reiterates Market Perform rating on the shares.
07/26/17
BERN
07/26/17
NO CHANGE
BERN
All of Biogen's key drugs performed well last quarter, says Bernstein
Bernstein analyst Aaron Gal says that all of Biogen's key drugs had high prescribing rates last quarter. The analyst says that concerns about the company's Spinraza drug are misplaced as it did well last quarter and is getting better coverage from payers. He thinks that opportunities in neurology justify the company's investment in this area. Gal keeps a $310 price target and an Outperform rating on the shares.
07/26/17
07/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Underperform at Jefferies with analyst Andy Barish saying the current valuation and consensus estimates "now reflect the reality" of Chipotle's path to recovery. 2. Biogen (BIIB) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying the company's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality. 3. DSW (DSW) upgraded to Outperform from Neutral at Wedbush with the firm saying it is more confident that second quarter results will beat expectations and that the company will reiterate its full-year guidance after conducting checks and speaking with the company. 4. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing a strong fiscal 2019 outlook. 5. Novartis (NVS) upgraded to Overweight from Underweight at Morgan Stanley with analyst Vincent Meunier upgrading the company two notches to Overweight from Underweight following a "massive" reset in consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$33.15

0.15 (0.45%)

06/29/17
JEFF
06/29/17
UPGRADE
Target $117
JEFF
Buy
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy saying the shares continue to trade at a group discount. The analyst sees "solid appreciation potential" as Pfizer (PFE) concentration is reduced and potentially 45% upside with a more aggressive acquisition strategy. The company's management has talked more openly about larger deals, Windley tells investors in a research note. Windley raised his price target for Icon shares to $117 from $86.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/20/17
FBCO
07/20/17
DOWNGRADE
Target $36
FBCO
Neutral
Pfizer downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan downgraded Pfizer to Neutral and lowered his price target for the shares to $36 from $38. The shares closed yesterday up 26c to $33.62. The analyst, who notes he's long been a supporter of Pfizer and continues to see opportunities for upside over the long-term, believes the stock's upside drivers are more limited over the next year. Divan prefers other names in the Major Pharmaceuticals space, such as Johnson & Johnson (JNJ) and Merck (MRK). Growth of Pfizer's Ibrance is slowing while global Prevnar sales are flat to declining, Divan tells investors in a research note. He adds that the company is facing two meaningful patent expirations over the next 18 months with Viagra, Lyrica.
07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SFST

Southern First Bancshares

$36.00

0.05 (0.14%)

17:50
08/16/17
08/16
17:50
08/16/17
17:50
Hot Stocks
Southern First Bancshares CFO Michael Dowling sells 5,850 shares »

Southern First Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BXE

Bellatrix Exploration

$2.40

-0.03 (-1.23%)

17:49
08/16/17
08/16
17:49
08/16/17
17:49
Hot Stocks
Bellatrix Exploration regains NYSE minimum price compliance »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:48
08/16/17
08/16
17:48
08/16/17
17:48
Hot Stocks
NetApp says headwind for services revenue to decrease in coming quarters »

Comments from Q1 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

ACHN

Achillion

$4.88

-0.12 (-2.40%)

17:45
08/16/17
08/16
17:45
08/16/17
17:45
Conference/Events
Achillion management to meet with William Blair »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BCOR

Blucora

$23.35

0.1 (0.43%)

, BBOX

Black Box

$3.75

-0.25 (-6.25%)

17:35
08/16/17
08/16
17:35
08/16/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Blucora (BCOR),…

BCOR

Blucora

$23.35

0.1 (0.43%)

BBOX

Black Box

$3.75

-0.25 (-6.25%)

BGG

Briggs & Stratton

$24.09

0.29 (1.22%)

LB

L Brands

$39.55

0.5 (1.28%)

VIPS

Vipshop

$11.10

-0.07 (-0.63%)

SPTN

SpartanNash

$25.96

0.07 (0.27%)

SNPS

Synopsys

$79.09

0.86 (1.10%)

CSCO

Cisco

$32.34

0.25 (0.78%)

NTAP

NetApp

$42.41

0.44 (1.05%)

LAKE

Lakeland Industries

$15.65

-0.25 (-1.57%)

GCP

GCP Applied Technologies

$28.75

0.1 (0.35%)

FNGN

Financial Engines

$34.35

-0.1 (-0.29%)

ACHC

Acadia

$51.68

-0.33 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 29

    Aug

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 14

    Sep

  • 30

    Nov

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

, WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

17:26
08/16/17
08/16
17:26
08/16/17
17:26
Upgrade
Andeavor Logistics, Western Refining Logistics rating change  »

Andeavor Logistics…

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$200.61

1.12 (0.56%)

17:22
08/16/17
08/16
17:22
08/16/17
17:22
Hot Stocks
General Dynamics awarded $115.3M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

BLVD

Boulevard Acquisition

$10.04

-0.01 (-0.10%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Hot Stocks
Breaking Hot Stocks news story on Boulevard Acquisition »

Glazer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$34.85

-0.33 (-0.94%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Syndicate
First Mid-Illinois Bancshares files to sell $20M of common stock 'at-the-market' »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

NCOM

National Commerce

$39.55

0.1 (0.25%)

17:16
08/16/17
08/16
17:16
08/16/17
17:16
Hot Stocks
National Commerce, FirstAtlantic Financial sign definitive merger agreement »

National Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMGN

Amgen

$171.39

1.35 (0.79%)

17:13
08/16/17
08/16
17:13
08/16/17
17:13
Hot Stocks
Amgen: NEJM publishes results from Repatha cognitive function trial »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 08

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

WLK

Westlake Chemical

$71.03

0.84 (1.20%)

17:13
08/16/17
08/16
17:13
08/16/17
17:13
Hot Stocks
Westlake Chemical CFO Mark Bender sells 13,794 shares of company stock »

Mark Bender, Westlake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBOX

Black Box

$3.75

-0.25 (-6.25%)

17:10
08/16/17
08/16
17:10
08/16/17
17:10
Hot Stocks
Black Box director John Heller buys 10,000 shares of company stock »

Black Box director John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCOR

Blucora

$23.35

0.1 (0.43%)

17:07
08/16/17
08/16
17:07
08/16/17
17:07
Hot Stocks
Blucora director retires from board effective August 10 »

Elizabeth J. Huebner, who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGG

Briggs & Stratton

$24.09

0.29 (1.22%)

17:06
08/16/17
08/16
17:06
08/16/17
17:06
Earnings
Briggs & Stratton sees FY18 EPS $1.31-$1.48, consensus $1.38 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGG

Briggs & Stratton

$24.09

0.29 (1.22%)

17:05
08/16/17
08/16
17:05
08/16/17
17:05
Earnings
Briggs & Stratton reports Q4 EPS 46c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.34

0.25 (0.78%)

17:02
08/16/17
08/16
17:02
08/16/17
17:02
Hot Stocks
Breaking Hot Stocks news story on Cisco »

Cisco says order booking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

MED

Medifast

$51.63

-0.4 (-0.77%)

16:58
08/16/17
08/16
16:58
08/16/17
16:58
Initiation
Medifast initiated  »

Medifast initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$12.11

-0.1 (-0.82%)

16:57
08/16/17
08/16
16:57
08/16/17
16:57
Hot Stocks
Daseke completes term loan amendment to support growth strategy »

Daseke announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

QEP

QEP Resources

$7.09

-0.2 (-2.74%)

16:55
08/16/17
08/16
16:55
08/16/17
16:55
Hot Stocks
Breaking Hot Stocks news story on QEP Resources »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.34

0.25 (0.78%)

16:50
08/16/17
08/16
16:50
08/16/17
16:50
Hot Stocks
Cisco to realign reporting into 5 distinct categories starting in 1Q18 »

Says innovation "as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

LB

L Brands

$39.55

0.5 (1.28%)

16:48
08/16/17
08/16
16:48
08/16/17
16:48
Hot Stocks
L Brands sees FY17 SSS down low to mid-single digits »

Sees FY17 SSS excluding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

LB

L Brands

$39.55

0.5 (1.28%)

16:46
08/16/17
08/16
16:46
08/16/17
16:46
Hot Stocks
L Brands sees Q3 SSS flat to down low-single digits »

Sees Q3 SSS excluding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

LGL

LGL Group

$4.31

0.0012 (0.03%)

16:40
08/16/17
08/16
16:40
08/16/17
16:40
Hot Stocks
LGL Group announces terms for rights offering »

The LGL Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLST

Netlist

$0.84

-0.06 (-6.67%)

16:37
08/16/17
08/16
16:37
08/16/17
16:37
Syndicate
Netlist files to sell common stock, no amount given »

Craig-Hallum Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.